SCHEMBL5584844

SCHEMBL5584844

COCOc1cccc2oc(C(=O)NN)cc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
GAA P10253 3/20 0.49
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 2/20 0.49
HTT P42858 1/20 0.45
F2RL3 Q96RI0 3/20 0.44
KMT2A Q03164 2/20 0.43
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
NMT2 O60551 1/20 0.41
NMT1 P30419 1/20 0.41
MMP2 P08253 2/20 0.41
MEN1 O00255 1/20 0.41
LMNA P02545 1/20 0.41
MMP13 P45452 1/20 0.40
CTSD P07339 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
CYP2A6 P11509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15349649 0.86 F2RL3 (0.46) MAPTGAAALDH1A1KDM4EHTT
SCHEMBL5584443 0.86 LMNA (0.48) MAPTALDH1A1KDM4EHTTF2RL3
SCHEMBL5585274 0.86 HTT (0.54) MAPTGAAALDH1A1KDM4EHTT
SCHEMBL15359239 0.83 F2RL3 (0.44) MAPTALDH1A1HTTF2RL3NMT2
SCHEMBL15349456 0.83 F2RL3 (0.43) MAPTALDH1A1HTTF2RL3NMT2
SCHEMBL5584843 0.81 F2RL3 (0.40) MAPTGAAALDH1A1HTTF2RL3
SCHEMBL28367862 0.79 NMT2 (0.50) MAPTKDM4EHTTF2RL3KMT2A
SCHEMBL29749775 0.77 LMNA (0.47) MAPTKDM4EHTTF2RL3L3MBTL1
SCHEMBL28372477 0.77 LMNA (0.47) MAPTKDM4EHTTF2RL3L3MBTL1
SCHEMBL29749333 0.76 F2RL3 (0.46) MAPTHTTF2RL3KMT2ANMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7196199-B2 Antiserotonine agents; antidepressants MITSUBISHI PHARMA CORPORATION (JP) 2007-03-27 US disclosed
EP-1188747-B1 PHENOXYPROPYLAMINE COMPOUNDS MITSUBISHI PHARMA CORP (JP) 2005-09-07 EP disclosed
US-20040138227-A1 Phenoxypropylamine compounds NISHIYAMA AKIRA 2004-07-15 US disclosed
US-6720320-B2 ANTISEROTONINE AGENTS MITSUBISHI PHARMA CORPORATION (JP) 2004-04-13 US disclosed
US-20020111358-A1 Phenoxypropylamine compounds MITSUBISHI PHARMA CORPORATION (JP) 2002-08-15 US disclosed
EP-1188747-A1 PHENOXYPROPYLAMINE COMPOUNDS Mitsubishi Pharma Corporation (JP) 2002-03-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138227-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPT 949/4885GAA 4054/4885ALDH1A1 443/4885
US-20020111358-A1 Phenoxypropylamine compounds HTR1A, HTR1D, HTR5A MAPT 949/4885GAA 4054/4885ALDH1A1 443/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.